Acalabrutinib Plus Rituximab “Highly Effective” in Older MCL Patients
Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.
Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.
A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.
Pirtobrutinib has shown clinical activity in a phase 1/2 trial of patients with relapsed or refractory mantle cell lymphoma.
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
A bispecific CAR T-cell therapy produced responses in 91% of patients with relapsed/refractory non-Hodgkin lymphoma in a phase 1 trial.
AbbVie and Janssen are withdrawing the accelerated approvals of Imbruvica for mantle cell lymphoma and marginal zone lymphoma.
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.